Alnylam Europe AG Company Profile

18:29 EDT 24th June 2018 | BioPortfolio

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbruch in der Biologie dar. Alnylams Produkt-Pipeline baut auf der RNAi als leistungsfähiger Plattform auf und hat zum Ziel, eine breitgefächerte neue Klasse von Therapeutika zur Behandlung einer Reihe von bedeutenden Erkrankungen hervorzubringen.
Alnylam wurde von führenden Wissenschaftlern gegründet, die zu den Pionieren bei der Entdeckung der RNAi gehören. Das Unternehmen setzt eine Technologie ein, mit der man sehr spezifisch und wirkungsvoll die Expression krankheitsverursachender Gene hemmen kann. Die RNAi ist ein natürlich vorkommender, zellulärer Prozess, durch den Gene spezifisch abgeschaltet werden können. Unter Ausnutzung dieses natürlichen Mechanismus entwickelt Alnylam neuartige Therapeutika, die selektiv solche Gene hemmen, deren Proteine eine schädliche Rolle bei der Krankheitsentstehung spielen.

Alnylam verfügt über hervorragende Voraussetzungen, um das Potenzial der RNAi für therapeutische Anwendungen voll auszuschöpfen. Alnylam ist das weltweit erste Unternehmen, das sich auf RNAi-Therapeutika spezialisiert hat. Es gründet sich auf die führende Expertise ihrer beiden operativen Einheiten, nämlich Alnylam Pharmaceuticals, Cambridge, Massachusetts, USA, gegründet im Jahr 2002, und der Ribopharma AG, Kulmbach, Deutschland, gegründet im Jahr 2000. Letztere firmiert heute unter Alnylam Europe AG und ist ein Tochterunternehmen von Alnylam Pharmaceuticals.


Fritz-Hornschuch-Str. 9


Phone: 49 9221 82762-0
Fax: 49 9221 82762-99

News Articles [259 Associated News Articles listed on BioPortfolio]

Alnylam gains rights to Sanofi's transthyretin-mediated amyloidosis candidates

Sanofi and Alnylam Pharmaceuticals amended their 2012 deal to give Alnylam global development and marketing rights to transth -More- 

Regeneron and Alnylam seek RNAi therapies for NASH

Regeneron and Alnylam are to research treatments for the chronic liver disease non-alcoholic steatohepatitis (NASH), under a new agreement. Alnylam specialises in treatments based around RNA interfer...

Alnylam and Sanofi enter into strategic restructuring

Alnylam Pharmaceuticals, Inc. and Sanofi announced a strategic restructuring of their RNAi therapeutics alliance to streamline and optimize development and commercialization of certain products for th...

Alnylam taps Agilent for commercial API supply

The five-year deal will help support Alnylam's planned market launch of its RNAi therapeutic patisiran.

EMA accepts for review Alnylam's hereditary ATTR amyloidosis drug

Alnylam Pharmaceuticals' marketing application for patisiran, which is being developed as a treatment for patients with hered -More- 

Alnylam and Sanofi restructure collaboration

Alnylam Pharmaceuticals and French pharma major Sanofi today announced a strategic restructuring of their…

Patisiran a launching pad for Alnylam venture into NASH research

Regeneron Pharmaceuticals and Alnylam Pharmaceuticals will collaborate to identify RNAi therapeutics…

Alnylam's hATTR amyloidosis drug accepted for FDA review

Alnylam Pharmaceuticals' patisiran, which is being developed as a treatment for patients with hereditary ATTR amyloidosis, wa -More- 

Drugs and Medications [4 Associated Drugs and Medications listed on BioPortfolio]

Nizatidine [Dispensing Solutions Inc.]

Nizatidine Capsules USP Rx only


Akne-mycin (Erythromycin)

Manicure by opi - finishing butter [OPI Products, Inc]


Retavase [EKR Therapeutics, Inc.]

Retavase Reteplase, recombinant

PubMed Articles [348 Associated PubMed Articles listed on BioPortfolio]

With Alnylam's amyloidosis success, RNAi approval hopes soar.

The genomic history of southeastern Europe.

Farming was first introduced to Europe in the mid-seventh millennium bc, and was associated with migrants from Anatolia who settled in the southeast before spreading throughout Europe. Here, to unders...

Infectious disease profiles of Syrian and Eritrean migrants presenting in Europe: A systematic review.

In the past decade, a large influx of migrants presented in Europe. Their country of origin was mainly either Syria or Eritrea. Public health institutions in host countries in Europe are challenged to...

Assisted reproductive technology in Europe, 2013: results generated from European registers by ESHRE.

Are there any changes in the treatments involving ART and IUI initiated in Europe during 2013 compared with previous years?

Hepatitis E virus genotypes and subgenotypes causing acute hepatitis, Bulgaria, 2013-2015.

In industrialized areas of the world, including Europe, Hepatitis E Virus (HEV) is considered an emerging pathogen. In fact, autochthonous cases caused by HEV genotype 3 (HEV-3) are increasingly repor...

Clinical Trials [571 Associated Clinical Trials listed on BioPortfolio]

In-market Utilisation of Liraglutide Used for Weight Management in Europe: a Retrospective Medical Record Review Study

This study is conducted in Europe. The aim of this study is to investigate usage of liraglutide for weight management in clinical practice.

RITE-EUROPE (Radiofrequency-Induced Thermochemotherapy Effect-EUROPE)

This multicenter, prospective, single-arm, phase 3 study will assess the proportion of disease-free patients, starting from administration of the first study treatment to at least 12-month...

EUROpE-RSI (EURopean Online Evaluation RSI Study)

The investigators want to identify and show differences in standards and procedures of in-hospital rapid sequence induction by collecting data with an online survey for anaesthetist in Eur...

A Study Measuring Quality of Life, Treatment Preference and Satisfaction of ADPKD Patients in Europe

This is a prospective, non-interventional study (NIS) measuring health-related quality of life (HRQoL), treatment satisfaction, and other patient-reported outcomes (PROs) of ADPKD patients...

PATHWAYS in Europe

PATHWAYS is a 3-year project that directly contributes to the 2014 Work Programme by focusing on action regarding the development of innovative approaches to promote the profession...

Companies [843 Associated Companies listed on BioPortfolio]

Alnylam Europe AG

Alnylam ist ein biopharmazeutisches Unternehmen, das neuartige Therapeutika auf Basis der RNA-Interferenz (RNAi) entwickelt und hierbei eine führende Position inne hat. Die RNAi stellt einen Durchbru...

Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, a leader in RNAi therapeutics, is a biopharmaceutical company developing novel therapeutics based on a breakthrough in biology known as RNA interference, or RNAi; a discovery ...

Alnylam Pharmaceuticals, Inc.

Alnylam is a biopharmaceutical company developing novel therapeutics based on RNA interference, or RNAi. The company is leading the translation of RNAi as a new class of innovative medicines with a ...

Alnylam Pharmaceuticals, Inc. and The Medicines Company

Europe Unlimited

Europe Unlimited profiles and connects the community of Europe’s best tech entrepreneurs and international capital through research, networking events and consulting. As such, we are in a position t...

More Information about "Alnylam Europe AG" on BioPortfolio

We have published hundreds of Alnylam Europe AG news stories on BioPortfolio along with dozens of Alnylam Europe AG Clinical Trials and PubMed Articles about Alnylam Europe AG for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alnylam Europe AG Companies in our database. You can also find out about relevant Alnylam Europe AG Drugs and Medications on this site too.

Quick Search


Relevant Topic

Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...

Corporate Database Quicklinks

Searches Linking to this Company Record